Literature DB >> 11059670

Aberrant p21 regulation in radioresistant primary glioblastoma multiforme cells bearing wild-type p53.

A Kraus1, M W Gross, R Knuechel, K Münkel, F Neff, J Schlegel.   

Abstract

OBJECT: A clearer understanding of the cellular mechanisms involved in the response to ionizing radiation is pivotal to the development of new therapeutic strategies for glioblastoma multiforme (GBM). To gain insight into dynamic functional aspects of cell cycle regulation and the control of apoptosis in GBMs, the authors investigated the molecular changes induced by ionizing radiation in genetically characterized primary GBMs in vitro compared with secondary GBMs, Grades II and III gliomas, and three GBM cell lines.
METHODS: Irradiation of primary GBMs bearing wild-type (wt) p53 invariably fails to invoke the G, checkpoint and apoptosis in vitro. In approximately half of these primary GBMs a defect lies at or above the level of p53 because transcriptional activation of p21 and bax after irradiation does not occur. The failure of a p21 response to irradiation is invariably accompanied by overexpression of p21 mRNA under nonirradiated conditions. In all remaining primary GBMs transcriptional activation of p21 after irradiation does occur, suggesting that a defect downstream from p21 prevents G, arrest.
CONCLUSIONS: These results show that the G, checkpoint and the p53 pathway are dysfunctional in primary GBMs in vitro, despite the presence of an intact p53 gene. The data also suggest that primary GBMs may be divided into two categories on the basis of their p21 response to irradiation.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11059670     DOI: 10.3171/jns.2000.93.5.0863

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  7 in total

Review 1.  Multiple functions of p21 in cancer radiotherapy.

Authors:  Yanbei Kuang; Jian Kang; Hongbin Li; Bingtao Liu; Xueshan Zhao; Linying Li; Xiaodong Jin; Qiang Li
Journal:  J Cancer Res Clin Oncol       Date:  2021-02-05       Impact factor: 4.553

Review 2.  Alterations in Molecular Profiles Affecting Glioblastoma Resistance to Radiochemotherapy: Where Does the Good Go?

Authors:  Juliana B Vilar; Markus Christmann; Maja T Tomicic
Journal:  Cancers (Basel)       Date:  2022-05-13       Impact factor: 6.575

3.  Immunohistochemical markers for prognosis of cerebral glioblastomas.

Authors:  Andrey Korshunov; Andrey Golanov; Regina Sycheva
Journal:  J Neurooncol       Date:  2002-07       Impact factor: 4.130

4.  Up-regulation of macrophage migration inhibitory factor gene and protein expression in glial tumor cells during hypoxic and hypoglycemic stress indicates a critical role for angiogenesis in glioblastoma multiforme.

Authors:  Michael Bacher; Jörg Schrader; Nancy Thompson; Karen Kuschela; Diethard Gemsa; Gérard Waeber; Jürgen Schlegel
Journal:  Am J Pathol       Date:  2003-01       Impact factor: 4.307

5.  Transcriptome analysis of glioma cells for the dynamic response to γ-irradiation and dual regulation of apoptosis genes: a new insight into radiotherapy for glioblastomas.

Authors:  H Ma; L Rao; H L Wang; Z W Mao; R H Lei; Z Y Yang; H Qing; Y L Deng
Journal:  Cell Death Dis       Date:  2013-10-31       Impact factor: 8.469

6.  The Effect of Sodium Valproate on the Glioblastoma U87 Cell Line Tumor Development on the Chicken Embryo Chorioallantoic Membrane and on EZH2 and p53 Expression.

Authors:  Dovilė Kavaliauskaitė; Donatas Stakišaitis; Justė Martinkutė; Lina Šlekienė; Arūnas Kazlauskas; Ingrida Balnytė; Vaiva Lesauskaitė; Angelija Valančiūtė
Journal:  Biomed Res Int       Date:  2017-05-31       Impact factor: 3.411

7.  A new lncRNA, APTR, associates with and represses the CDKN1A/p21 promoter by recruiting polycomb proteins.

Authors:  Masamitsu Negishi; Somsakul P Wongpalee; Sukumar Sarkar; Jonghoon Park; Kyung Yong Lee; Yoshiyuki Shibata; Brian J Reon; Roger Abounader; Yutaka Suzuki; Sumio Sugano; Anindya Dutta
Journal:  PLoS One       Date:  2014-04-18       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.